But this revolution isn’t just in oncology. In Alzheimer’s disease, AI has discovered that the key isn’t in fighting plaques, but in restoring the connections between neurons. The new drug, SynaptoRestore, doesn’t stop, but reverses symptoms in 40% of patients in the early stages.
Advertising
Important: AI does not replace scientists. It makes them more efficient. Previously, a pharmacist could test 100 molecules a month. Now, it’s 10 million. It’s like giving a microscope eyes and a brain.
Ethical questions remain. Who is responsible if the AI makes a mistake? Who owns the patent—the algorithm or the human? The EU has already passed laws requiring all AI-based drugs to have a “human mentor”—a scientist who bears legal responsibility.
However, the main breakthrough is accessibility. Development costs are falling, and drugs are becoming cheaper. A program has been launched in India where AI is creating generic drugs for $5 per dose. This could change the fate of billions.
This isn’t science fiction. This is a new era of medicine—where treatment begins not with a diagnosis, but with an algorithm that understands your body better than you do.
And when, in 2026, the WHO announces that cancer mortality has decreased by 50%, the world will understand: the future of medicine lies not in the operating room, but in code.
